Decent quarter for GlaxoSmithKline with traction in generic medicines and speciality business and cost optimization resulted in highest margins | Glaxosmithkline Pharmaceuticals Q2 FY23 Result Analysis
Decent quarter for GlaxoSmithKline with traction in generic medicines and speciality business and cost optimization resulted in highest margins | Glaxosmithkline Pharmaceuticals Q2 FY23 Result Analysis
Decent quarter for GlaxoSmithKline with traction in generic medicines and speciality business and cost optimization resulted in highest margins | Glaxosmithkline Pharmaceuticals Q2 FY23 Result Analysis
Published on 15 November 2022 .Views 11.Comments 0